Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
NCT07929740, Phase 1, Not yet recruiting, Kura Oncology, Inc.
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS | ClinicalTrials.gov |
| NCT number | NCT07929740 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 1 | ClinicalTrials.gov |
| Enrollment | 126 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Kura Oncology, Inc. | ClinicalTrials.gov |
| Conditions | Myelodysplastic Syndrome (MDS)/AML, Myeloid Leukemia, Acute | ClinicalTrials.gov |
| Interventions | Ziftomenib, Ziftomenib, Ziftomenib, Ziftomenib | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A, B and C) | During the first 56 days of ziftomenib | Maximum plasma concentration at steady state (Cmax,ss) | ClinicalTrials.gov |
| Primary | To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A and B) | During the first 56 days of ziftomenib | Plasma concentration observed at end of dosing interval at steady state (Cτ) | ClinicalTrials.gov |
| Primary | To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A, B and C) | During the first 56 days of ziftomenib | Area under the concentration-time curve from time 0 to dosing interval at steady state (AUC0-τ,ss) | ClinicalTrials.gov |
| Primary | To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A and B) | During the first 56 days of ziftomenib | Time to Cmax,ss (Tmax,ss) | ClinicalTrials.gov |
| Primary | To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A and B) | During the first 56 days of ziftomenib | Cavg,ss | ClinicalTrials.gov |
| Secondary | To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohort C) | During the first 56 days of ziftomenib | Cτ | ClinicalTrials.gov |
| Secondary | To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohort C) | During the first 56 days of ziftomenib | Tmax,ss | ClinicalTrials.gov |
| Secondary | To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohort C) | During the first 56 days of ziftomenib | Cavg,ss | ClinicalTrials.gov |
| Secondary | To assess safety and tolerability of ziftomenib (Parts 1 and 2) | Day 1 of study intervention through 28 days after the last dose | 1. Incidence and severity of AEs per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI CTCAE) V6.0 2. Incidence of SAEs | ClinicalTrials.gov |
| Secondary | To assess discontinuation of study treatment due to Adverse Events (Parts 1 and 2) | Day 1 of study intervention through 28 days after the last dose | Discontinuation of study treatment due to AEs | ClinicalTrials.gov |
| Secondary | To assess deaths while receiving treatment (Parts 1 and 2) | Day 1 of study intervention through 28 days after the last dose | Deaths on treatment | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)